An orally-active agent with potential antineoplastic activity. Carboxyamidotriazole binds to and inhibits non-voltage-operated Ca2+ channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores and resulting in the disruption of calcium channel-mediated signal transduction and inhibition of vascular endothelial growth factor (VEGF) signaling, endothelial proliferation, and angiogenesis. This agent may also inhibit tumor cell growth, invasion and metastasis. OR A chemotherapy combination used to treat advanced, nonsquamous non-small cell lung cancer. It includes the drugs carboplatin, paclitaxel (Taxol), and bevacizumab. Also called carboplatin-paclitaxel-bevacizumab regimen.